Jay Olson
Stock Analyst at Oppenheimer
(4.29)
# 349
Out of 5,182 analysts
254
Total ratings
45.59%
Success rate
19.69%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Perform | $84 → $90 | $96.91 | -7.13% | 15 | Apr 29, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Perform | n/a | $52.93 | - | 5 | Apr 27, 2026 | |
| PASG Passage Bio | Maintains: Outperform | $30 → $15 | $4.97 | +201.81% | 2 | Apr 21, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $150 → $165 | $139.48 | +18.30% | 11 | Apr 13, 2026 | |
| BIIB Biogen | Maintains: Outperform | $250 → $275 | $187.06 | +47.01% | 27 | Apr 1, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $44 → $36 | $4.80 | +650.00% | 5 | Mar 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $540 → $600 | $423.92 | +41.54% | 2 | Mar 10, 2026 | |
| BIOA BioAge Labs | Initiates: Outperform | $60 | $16.79 | +257.36% | 1 | Feb 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $21.95 | +4.78% | 16 | Feb 6, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.80 | +455.56% | 1 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $250 → $750 | $324.20 | +131.34% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $650 | $513.72 | +26.53% | 12 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.59 | +214.47% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $75.27 | +19.57% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.37 | +458.66% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $4.14 | +238.16% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.64 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.14 | +1,970.06% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $0.93 | +6,886.99% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.10 | +1,081.82% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $86.46 | +4.09% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $18.30 | +129.51% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $43.68 | -24.45% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $13.26 | +201.66% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $5.04 | +296.83% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $7.61 | +294.22% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $30.00 | +360.00% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.88 | +325.53% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $329.82 | +15.21% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $131.78 | +66.19% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.90 | +313.79% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.76 | +378.72% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $35.59 | +180.98% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $51.63 | +84.00% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.82 | +2,935.82% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.28 | +603.13% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.68 | +29,661.90% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.35 | +46.34% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.64 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.63 | +405.11% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.07 | - | 3 | Jul 11, 2017 |
Incyte
Apr 29, 2026
Maintains: Perform
Price Target: $84 → $90
Current: $96.91
Upside: -7.13%
Terns Pharmaceuticals
Apr 27, 2026
Downgrades: Perform
Price Target: n/a
Current: $52.93
Upside: -
Passage Bio
Apr 21, 2026
Maintains: Outperform
Price Target: $30 → $15
Current: $4.97
Upside: +201.81%
Revolution Medicines
Apr 13, 2026
Maintains: Outperform
Price Target: $150 → $165
Current: $139.48
Upside: +18.30%
Biogen
Apr 1, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $187.06
Upside: +47.01%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $44 → $36
Current: $4.80
Upside: +650.00%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $540 → $600
Current: $423.92
Upside: +41.54%
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $16.79
Upside: +257.36%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $21.95
Upside: +4.78%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.80
Upside: +455.56%
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $324.20
Upside: +131.34%
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $513.72
Upside: +26.53%
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $1.59
Upside: +214.47%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $75.27
Upside: +19.57%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.37
Upside: +458.66%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.14
Upside: +238.16%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.64
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.14
Upside: +1,970.06%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $0.93
Upside: +6,886.99%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.10
Upside: +1,081.82%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $86.46
Upside: +4.09%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $18.30
Upside: +129.51%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $43.68
Upside: -24.45%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $13.26
Upside: +201.66%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $5.04
Upside: +296.83%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $7.61
Upside: +294.22%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $30.00
Upside: +360.00%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.88
Upside: +325.53%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $329.82
Upside: +15.21%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $131.78
Upside: +66.19%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.90
Upside: +313.79%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.76
Upside: +378.72%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $35.59
Upside: +180.98%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $51.63
Upside: +84.00%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.82
Upside: +2,935.82%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.28
Upside: +603.13%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.68
Upside: +29,661.90%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.35
Upside: +46.34%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.64
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.63
Upside: +405.11%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.07
Upside: -